Bone tumours of the clavicle: Histopathological, anatomical and epidemiological analysis of 113 cases
ConclusionsThe high incidence of malignant bone tumours of the clavicle found in this study highlight the importance of biopsy to prevent delay in diagnosis and treatment of these lesions, especially in patients with increased age. We believe that the results of this study are of clinical importance and may aid the physician in the management of these rare lesions. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - March 30, 2019 Category: Cancer & Oncology Source Type: research
Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer
Publication date: Available online 7 November 2018Source: Journal of Bone OncologyAuthor(s): Xinge Shi, Xiqing Li, Hongqiang Wang, Zhenghong Yu, Yu Zhu, Yanzheng GaoABSTRACTImpressive responses have been observed in patients with cancer treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies through disinhibiting the immune system. However, tumors possess complex immunosuppressive tumor microenvironment to present therapeutic obstacles and the response rates to immune checkpoint inhibition remain low. One significant barrier to the effic...
Source: Journal of Bone Oncology - March 20, 2019 Category: Cancer & Oncology Source Type: research
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
Publication date: Available online 19 March 2019Source: Journal of Bone OncologyAuthor(s): Alexandros Stamatopoulos, Theodosios Stamatopoulos, Zakareya Gamie, Eustathios Kenanidis, Ricardo Da Conceicao Ribeiro, Kenneth Samora Rankin, Craig Gerrand, Kenneth Dalgarno, Eleftherios TsiridisAbstractOver the past few decades, there has been growing interest in understanding the molecular mechanisms of cancer pathogenesis and progression, as it is still associated with high morbidity and mortality. Current management of large bone sarcomas typically includes the complex therapeutic approach of limb salvage or sacrifice combined w...
Source: Journal of Bone Oncology - March 20, 2019 Category: Cancer & Oncology Source Type: research
Dovitinib dilactic acid reduces tumor growth and tumor-induced bone changes in an experimental breast cancer bone growth model
In this study we used FGFR1 and FGFR2 gene amplifications containing human MFM223 breast cancer cells in an experimental xenograft model of breast cancer bone growth using intratibial inoculation technique. This model mimics bone metastases in breast cancer patients. The effects of an FGFR inhibitor, dovitinib dilactic acid (TKI258) on tumor growth and tumor-induced bone changes were evaluated. Cancer-induced bone lesions were smaller in dovitinib-treated mice as evaluated by X-ray imaging. Peripheral quantitative computed tomography imaging showed higher total and cortical bone mineral content and cortical bone mineral de...
Source: Journal of Bone Oncology - March 20, 2019 Category: Cancer & Oncology Source Type: research
Endoplasmic Reticulum Protein 29 (ERp29) as a Novel Prognostic Marker and Tumor Suppressor in Osteosarcoma
Conclusions: These findings suggest a tumor suppressive role of ERp29 in osteosarcoma. In addition, ERp29 might potentially be applied as a prognostic indicator in patients with osteosarcoma. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - March 20, 2019 Category: Cancer & Oncology Source Type: research
Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study
ConclusionsAdvanced age (older than 30 years) and large tumors were related to a higher risk of lung metastases in osteosarcoma patients. Therefore, patients who were diagnosed at advanced age or had large tumors should receive comprehensive chest CT scans. Surgery and chemotherapy can significantly improve the survival of metastatic patients, while radiotherapy did not improve survival in these patients. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - March 9, 2019 Category: Cancer & Oncology Source Type: research
Bone tumours of the clavicle: histopathological, anatomical and epidermiological analysis of 113 cases
ConclusionsBone tumours of the clavicle seem to have different histopathological and epidermiological characteristics than bone tumours at other sites. A high index of suspicion should be maintained when evaluating patients with clavicular lesions due to the high incidence of malignancy, especially in patients with increased age. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - March 6, 2019 Category: Cancer & Oncology Source Type: research
Long noncoding RNA UCA1 promotes osteosarcoma metastasis through CREB1-mediated epithelial-mesenchymal transition and activating PI3K/AKT/mTOR pathway
In this study, we firstly found UCA1 is upregulated in both osteosarcoma tissues and cell lines, and increased UCA1 is associated with higher tumor stage, larger tumor size and poorer prognosis. Then for the first time, we demonstrated that UCA1 promotes the invasion and metastasis of osteosarcoma both in vitro and in vivo. Further mechanistic investigation showed that UCA1 directly interactes with miR-582 and suppresses its expression. Moreover, UCA1 increases CREB1 expression by functioning as a ceRNA against miR-582, thus promoting the EMT process via CREB1-mediated PI3K/AKT/mTOR pathway and finally leading to osteosarc...
Source: Journal of Bone Oncology - March 1, 2019 Category: Cancer & Oncology Source Type: research
mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model
Publication date: Available online 27 February 2019Source: Journal of Bone OncologyAuthor(s): Chiara Spadazzi, Federica Recine, Laura Mercatali, Giacomo Miserocchi, Chiara Liverani, Alessandro De Vita, Alberto Bongiovanni, Valentina Fausti, Toni IbrahimAbstractThe skeleton is one of the most common sites of metastatic spread from advanced clear-cell renal carcinoma (ccRCC). Most of the bone lesions observed in RCC patients are classified as osteolytic, causing severe pain and morbidity due to pathological bone destruction. Nowadays, it is well known that cancer induced bone loss in lytic metastasis is caused by the trigger...
Source: Journal of Bone Oncology - February 28, 2019 Category: Cancer & Oncology Source Type: research
Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
ConclusionsPrevalence of severe side effects in a ‘real world’ population of PM women receiving adjuvant BPs is low and these drugs are generally well accepted and tolerated by patients. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 19, 2019 Category: Cancer & Oncology Source Type: research
Bone transport using the Ilizarov method for osteosarcoma patients with tumor resection and neoadjuvant chemotherapy
ConclusionBone transport using the Ilizarov method can achieve good therapeutic effectiveness in the limb-salvage treatment for OS patients with neoadjuvant chemotherapy as long as the complications can be timely recognized and well managed. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 13, 2019 Category: Cancer & Oncology Source Type: research
A Nomogram to Predict Prognosis in Ewing sarcoma of bone
ConclusionOur nomogram is a reliable and powerful tool for distinguishing and predicting the survival of ES patients, thus helping to better select medical examinations and optimize treatment options in collaboration with medical oncologists and surgeons. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 13, 2019 Category: Cancer & Oncology Source Type: research
Prediction of survival after surgical management of femoral metastatic bone disease – a comparison of prognostic models
ConclusionsAmong six prognostic models assessed in the setting of femoral metastatic bone disease, the present study observed the most accurate model for 3-month, 6-month, 12-month and 24-month survival. The results of this study may be utilised by the treating surgical team to determine the most accurate model for the required time period and therefore improve decision-making in the care of patients with femoral metastatic bone disease. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - February 13, 2019 Category: Cancer & Oncology Source Type: research
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Publication date: Available online 29 January 2019Source: Journal of Bone OncologyAuthor(s): Pichaya Thanindratarn, Dylan C. Dean, Scott D. Nelson, Francis J. Hornicek, Zhenfeng DuanAbstractBone sarcomas are a collection of sporadic malignancies of mesenchymal origin. The most common subtypes include osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. Despite the use of aggressive treatment protocols consisting of extensive surgical resection, chemotherapy, and radiotherapy, outcomes have not significantly improved over the past few decades for osteosarcoma or Ewing sarcoma patients. In addition, chondrosarcoma and ...
Source: Journal of Bone Oncology - January 30, 2019 Category: Cancer & Oncology Source Type: research
Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
ConclusionsmTOR inhibition leads to a reduction of oxidative and glycolytic metabolism and decreased proliferation in chondrosarcoma cell lines. Although further research is needed, these findings suggest that mTOR inhibition might be a potential therapeutic option for patients with chondrosarcoma. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - January 30, 2019 Category: Cancer & Oncology Source Type: research
